Andrew Obenshain, an officer and director of bluebird bio, is set to sell 971 shares of common stock on 12/10/2024, with an aggregate market value of $436.95. The shares originate from vested restricted stock units acquired on 11/02/2020 under the company's equity plan, with the sale primarily due to withholding taxes.The transaction is part of a planned sale instruction given on 05/10/2023. Notably, Obenshain has previously sold 34,780 shares of common stock on 09/30/2024, generating gross proceeds of $18,269.This upcoming sale represents a continuation of Obenshain's recent trading activity in bluebird bio stock, potentially reflecting pre-planned diversification or tax management strategies typical for company executives.

Andrew Obenshain, an officer and director of bluebird bio, is set to sell 971 shares of common stock on 12/10/2024, with an aggregate market value of $436.95. The shares originate from vested restricted stock units acquired on 11/02/2020 under the company's equity plan, with the sale primarily due to withholding taxes.The transaction is part of a planned sale instruction given on 05/10/2023. Notably, Obenshain has previously sold 34,780 shares of common stock on 09/30/2024, generating gross proceeds of $18,269.This upcoming sale represents a continuation of Obenshain's recent trading activity in bluebird bio stock, potentially reflecting pre-planned diversification or tax management strategies typical for company executives.